Search

everythinglearnresearchcommunity

for

Search:↓

Compound 4 is a promising treatment for hair loss with low toxicity.

Baricitinib works better in adolescents than adults for treating severe alopecia areata.

Targeted cancer therapies can cause skin side effects, but activating SOS in the skin may help reduce them.

Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.

DNA analysis can help tailor alopecia treatment.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Genetic profiling can improve androgenetic alopecia treatment by predicting drug response and minimizing side effects.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.

Erlotinib can cause hair loss as a side effect.

Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.

Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.

PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.

An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.

Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

The research identified genes linked to male-pattern baldness and potential drug targets for treatment.

Erlotinib can cause hair loss and texture changes.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Early sunburn treatment with certain inhibitors may reduce skin cancer risk.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.